FR209602 and Related Compounds, Novel Antifungal Lipopeptides from Coleophoma crateriformis No. 738

@article{Kanasaki2006FR209602AR,
  title={FR209602 and Related Compounds, Novel Antifungal Lipopeptides from Coleophoma crateriformis No. 738},
  author={Ryuichi Kanasaki and Kazutoshi Sakamoto and Michizane Hashimoto and Shigehiro Takase and Yasuhisa Tsurumi and Akihiko Fujie and Motohiro Hino and Seiji Hashimoto and Yasuhiro Hori},
  journal={The Journal of Antibiotics},
  year={2006},
  volume={59},
  pages={137-144}
}
Novel antifungal lipopeptides, FR209602, FR209603 and FR209604, were isolated from the fermentation broth of a fungal strain No. 738 which was identified as Coleophoma crateriformis from morphological and physiological characteristics. The antibiotics were purified by solvent extraction, HP-20, YMC-ODS and silica gel column chromatography and lyophilization. These compounds were structurally similar to FR901379 previously reported by ourselves which had a sulfate residue in the cyclic peptide… 
FR227673 and FR190293, Novel Antifungal Lipopeptides from Chalara sp. No. 22210 and Tolypocladium parasiticum No. 16616
Novel antifungal lipopeptides, FR227673 and FR190293, were isolated from the fermentation broths of fungal strains Chalara sp. No. 22210 and Tolypocladium parasiticum No. 16616, respectively. These
Micafungin: a sulfated echinocandin
  • S. Hashimoto
  • Biology, Chemistry
    The Journal of Antibiotics
  • 2009
Micafungin is the second approved antifungal agent in the echinocandin series and is now used worldwide in chemotherapy for life-threatening fungal infections. It is water-soluble and is
New insights into the echinocandins and other fungal non-ribosomal peptides and peptaibiotics.
TLDR
An update on new peptides, depsipeptides and peptaibols discovered in the Fungi since 2009 and a comparative analysis of how pathway genes cause variations in lipoinitiation, biosynthesis of the non-proteinogenic amino acids, amino acid substitutions, and hydroxylations and sulfonations of the core peptide contribute to the molecular diversity of the family.
Non-β-Lactam Antibiotics
TLDR
Some classes of fungal metabolites which are presently used as medicinal, veterinary or agricultural antibiotics, as well as some newer candidates for development are reviewed.
Antimicrobial lipopeptides: in vivo and in vitro synthesis
TLDR
This review starts with general comments on antimicrobial peptides (AMPs), a large family of compounds that includes non-ribosomally assembled lipopeptides that have potential environmental and medical applications, but limited productivity.
Echinocandins: structural diversity, biosynthesis, and development of antimycotics
TLDR
An overview of the current knowledge of echinocandin biosynthesis with a special focus of the diverse structural elements, their biosynthetic background, and structure−activity relationships is provided.
Structural diversity in echinocandin biosynthesis: the impact of oxidation steps and approaches toward an evolutionary explanation
  • Wolfgang Hüttel
  • Biology, Chemistry
    Zeitschrift fur Naturforschung. C, Journal of biosciences
  • 2017
TLDR
An overview of the current knowledge of echinocandin biosynthesis with a special focus on diversity-inducing oxidation steps is provided and the formation of metabolic diversity in a single organism is analyzed.
Emergence of Candida spp. and exploration of natural bioactive molecules for anticandidal therapy –status quo
TLDR
The exploration of drugs from natural resources serves as a better alternative source in anticandidal therapeutics, having great scope for drug discovery in the future.
...
...

References

SHOWING 1-10 OF 29 REFERENCES
FR209602 and Related Compounds, Novel Antifungal Lipopeptides from Coleophoma crateriformis No. 738
TLDR
The biological activities of the novel echinocandin-like lipopeptides, FR209602,FR209603 and FR209604, showed antifungal activity against Candida albicans and Aspergillus fumigatus attributed to inhibition of 1,3-β-glucan synthesis.
WF11899A, B and C, novel antifungal lipopeptides. I. Taxonomy, fermentation, isolation and physico-chemical properties.
TLDR
WF11899A, B and C, novel antifungal lipopeptide antibiotics were isolated from the culture broth of Coleophoma empetri F-11899 and showed good solubility in water.
Mulundocandin, a new lipopeptide antibiotic. I. Taxonomy, fermentation, isolation and characterization.
Mulundocandin, a new lipopeptide antibiotic, was isolated from the culture broth of a strain of Aspergillus sydowi No. Y-30462. The antibiotic, obtained as a colorless amorphous powder having the
MULUNDOCANDIN, A NEW LIPOPEPTIDE ANTIBIOTIC
Mulundocandin, a new lipopeptide antibiotic, was isolated from the culture broth of a strain of Aspergillus sydowi No. Y-30462. The antibiotic, obtained as a colorless amorphous powder having the
WF11899A, B and C, novel antifungal lipopeptides. II. Biological properties.
TLDR
WF11899A, B and C, novel water-soluble lipopeptides related to the echinocandins, possess potent anti-Candida activities and mildly suppressed the growth of Aspergillus fumigatus and A. niger.
Studies on aculeacin. I. Isolation and characterization of aculeacin A.
TLDR
The antibiotic showed a potent activity against molds and yeasts, but exhibited no antibacterial activity, and has relatively low toxicity in mice.
STUDIES ON ACULEACIN
TLDR
The antibiotic showed a potent activity against molds and yeasts, but exhibited no antibacterial activity, and has relatively low toxicity in mice.
Pneumocandins from Zalerion arboricola. I. Discovery and isolation.
HPLC bioautography of the directed biosynthesis of Zalerion arboricola led to the discovery of pneumocandin B0 (L-688,786), a new antifungal and anti-Pneumocystis carinii lipopeptide. Isolation
L-671,329, a new antifungal agent. I. Fermentation and isolation.
TLDR
A new lipopeptide antifungal agent, similar to echinocandin B, has been isolated from Zalerion arboricola and studies indicate that L-671,329 is produced under both solid and liquid fermentation conditions.
Deacylation of echinocandin B by Actinoplanes utahensis.
TLDR
The ECB nucleus, which contained a new titratable group at the N-terminus, was subsequently employed for chemical reacylation with other side chains to yield a variety of novel ECB analogs, including cilofungin, which is currently undergoing clinical evaluation.
...
...